In Reply: Neoadjuvant TKI Study in Early- and Intermediate Stage Hepatocellular Carcinoma

Susanne Osanto; F J Sherida H Woei-A-Jin; Minneke J Coenraad; Nir I Weijl; Mark C Burgmans; Jacobus Burggraaf

doi:10.1093/oncolo/oyac215

In Reply: Neoadjuvant TKI Study in Early- and Intermediate Stage Hepatocellular Carcinoma

Oncologist. 2022 Dec 9;27(12):e977-e978. doi: 10.1093/oncolo/oyac215.

Authors

Susanne Osanto^{1

2}, F J Sherida H Woei-A-Jin^{1

2}, Minneke J Coenraad³, Nir I Weijl¹, Mark C Burgmans⁴, Jacobus Burggraaf⁵

Affiliations

¹ Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands.
² Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, The Netherlands.
³ Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, The Netherlands.
⁴ Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands.
⁵ Center for Human Drug Research, Leiden, The Netherlands.

Abstract

This letter to the editor responds to comments from Rizzo et al on recently reported results of a phase II study of dovitinib therapy for hepatocellular carcinoma.

Publication types

Editorial
Comment

MeSH terms

Carcinoma, Hepatocellular* / drug therapy
Humans
Liver Neoplasms* / drug therapy
Neoadjuvant Therapy